U.S. Physical Therapy, Inc. (USPH) Stock Price & How to Invest
Last updated November 2026
Short answer
U.S. Physical Therapy (USPH) is a Houston operator of about 799 outpatient physical therapy clinics plus an industrial injury prevention business, and you can own it through shares or fractional shares at most brokers or through small-cap healthcare ETFs. It is a steady, partnership-driven roll-up whose 2027 story rests on new hospital affiliations. As of November 20, 2026 the stock closed at about $96.16, a market cap near $1.44 billion, up about 22% year to date and about 41% over one year.
USPH stock price
As of 2026-11-20, U.S. Physical Therapy, Inc. (USPH) last closed at $95.93, up 33.9% over the past year. Over the past 52 weeks it has traded between $59.00 and $100.10.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or U.S. Physical Therapy, Inc.'s investor relations page. Walnut is informational, not investment advice.
USPH key stats
At $95.93 on November 20, 2026, U.S. Physical Therapy, Inc. (USPH) has a market cap of $1.4B and a dividend yield of 1.92%.
- Market cap
- $1.4B
- P/E (forward)
- 28.5
- Price to book
- 3.3
- Dividend yield
- 1.92%
- Beta
- 1.13
Market cap, P/E and yield are measured at the $95.93 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with U.S. Physical Therapy, Inc. (USPH)?
The last two weeks for U.S. Physical Therapy, Inc., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- USPH closed at $95.93 on November 20, 2026, down 3.7% over the past five trading days (from $99.60).
- On November 13, 2026, Barrington Research raised its target to $122.00 from $110.00 (Outperform).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does U.S. Physical Therapy, Inc. (USPH) do?
U.S. Physical Therapy, Inc. runs outpatient physical and occupational therapy clinics across the United States, about 799 locations at September 30, 2026, and an industrial injury prevention (IIP) business that sends athletic trainers and ergonomic specialists into employer worksites. Physical therapy produced about $190 million of Q3 2026 revenue and IIP about $33 million. The company's model is unusual: it buys a majority stake in a local practice, often 50% to 70%, and the founding therapists keep the rest and keep running it. That keeps clinicians invested, but it also means a large slice of profit belongs to partners, and the value of their stakes runs through earnings per share.
The Q3 2026 report on November 4 was the company's strongest quarter of the year. Revenue rose 13% to about $223 million, patient visits rose 8% to 1.7 million, revenue per visit reached a record $111, and adjusted EBITDA climbed to about $28 million from $24 million. Adjusted EPS was $0.80 against $0.66 a year earlier, even though GAAP showed a loss of $1.04 per share because partner stakes were revalued higher. All 72 clinics under two hospital affiliations, including a 10-year alliance with NYU Langone, were integrated by quarter end and produced about $25 million of revenue. Management reaffirmed 2026 adjusted EBITDA guidance of $102 million to $106 million and kept the quarterly dividend at $0.46.
The shares had a rough first half. A weather-hit Q1, with more than 31,000 lost visits, and a Q2 adjusted EPS miss ($0.75 against roughly $0.84 expected) pushed the stock to about $59 in May. It recovered through the summer and then rose from about $85 on November 3 to about $99.50 on November 6, close to its 52-week high of about $101.80, before settling at about $96.16 on November 20. At that price USPH trades around 36x trailing adjusted EPS of about $2.68 and roughly 17x to 20x trailing adjusted EBITDA, depending on whether partner stakes are counted. Barrington raised its price target twice after the report, to $110 from $98 and then to $122, and the mean target across six analysts is about $111.50. Investors are paying for 2027 margin gains from the hospital clinics, and rising self-insured employee health costs are the main thing eating into those gains today.
What's driving U.S. Physical Therapy, Inc. (USPH)?
1. Hospital affiliations
In February 2026 USPH announced two 10-year alliances. Under the first, 60 clinics run by its Metro subsidiary in New York joined NYU Langone's clinical network; under the second, 10 clinics joined a local hospital system. By Q3 the count was 72 clinics, all integrated, generating about $25 million of revenue in the quarter. Hospital-affiliated clinics typically earn higher rates than independent clinics, and management said it expects that revenue to grow significantly as referrals rise, more clinics are added to existing agreements and new hospital deals close. Earlier in the year management talked about at least $14 million of EBITDA lift in 2027 from the original clinics, which would be meaningful against 2026 guidance of $102 million to $106 million.
2. Visit volume and rate per visit
The core engine is simple: more visits per clinic at a higher price per visit. Q3 2026 brought 1.7 million visits, up 8%, with average daily visits per clinic of 33 against 32 a year earlier, and revenue per visit of $111, up $5. Mature clinics grew revenue 6%, the best rate this year (3.5% in Q2). Medicare is a large payer, and the 2026 physician fee schedule gave therapists a modest increase after several years of cuts; guidance included about $2.5 million from Medicare rate changes. Commercial contract renegotiations and growth in cash-pay programs make up the rest of the rate story.
3. Acquisitions under the partnership model
USPH grows by buying controlling stakes in established practices. In 2026 it bought 50% of an eight-clinic practice in January (about $8 million of annual revenue), 70% of an IIP business in January (about $7 million) and 67% of a 12-clinic practice in July for about $16 million (about $12 million of revenue), roughly $37.6 million in total. A new $450 million credit facility closed in April 2026, with a $175 million term loan and a $275 million revolver due 2031, which funds this pace. Borrowings rose to $247 million at September 30 from $162 million at year end, still modest against about $100 million of annual adjusted EBITDA.
4. Industrial injury prevention and cost control
IIP is the smaller, higher-margin side of the business. Q3 revenue was about $33 million, up 14% (8% excluding the January acquisition), and margin improved to 22% from 20%. Employers pay for on-site trainers to cut workplace injury claims, so the work is less exposed to Medicare and insurers. On costs, the company has partly moved front-desk work to virtual staff and says expense controls put in place during Q3 will help later periods. The open item is the self-insured employee medical plan: higher health benefit costs took about 150 basis points off physical therapy margin in Q3, so adjusted PT margin of about 19% would have been higher without them.
What are the risks to U.S. Physical Therapy, Inc. (USPH)?
Reimbursement is the largest outside risk. Medicare cut therapy rates for several years before 2026, and part of the 2026 increase came from a one-year boost set by Congress, so a cut in the 2027 fee schedule would hit revenue per visit directly. Commercial insurers can also push rates down or tighten visit limits. Labor is the second: physical therapists are in short supply, wages keep rising, and the company's self-insured health plan has been running well above last year's costs. The partnership structure adds complexity. Partners hold about $357 million of redeemable stakes that USPH may have to buy back under put rights, and their rising value has pushed GAAP EPS negative in three of the last four quarters (a $1.04 loss in Q3) even as adjusted earnings grew. The hospital affiliations are concentrated, with 60 of the 72 clinics tied to one New York system, and the company lists termination of an affiliation as a risk. Weather and seasonality move results, as the 31,000 lost visits in Q1 showed. The CFO seat turned over this year, with Nchacha Etta (formerly of Omnicell) starting September 1. Finally, after the jump to about $99.50 and a close near $96 on November 20, 2026, the stock trades within about 15% of the mean analyst target of roughly $111.50, so the cushion between price and published expectations is thin.
What is the U.S. Physical Therapy, Inc. (USPH) forecast?
6 analysts publish price targets on USPH, averaging $111.50 as of November 2026, or +16.2% against the $95.93 share price on November 20, 2026. The published targets run from $95.00 to $122.00, a narrow spread, and the ratings split 6 buy, 1 hold, 0 sell. Over the last six months there have been 4 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full USPH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is USPH a buy or a sell?
We give no verdict on U.S. Physical Therapy, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Hospital affiliations. In February 2026 USPH announced two 10-year alliances. The most optimistic published target, $122.00, assumes this works close to its best case.
The case against. Reimbursement is the largest outside risk. The most pessimistic target, $95.00, is roughly what USPH is worth if this bites instead.
Read the full bull and bear case on USPH, including what would have to change to break either one. Walnut is not an investment adviser.
How is U.S. Physical Therapy, Inc. (USPH) valued?
Market cap, P/E and dividend yield at today's price are in the USPH key stats above. The business figures below come from U.S. Physical Therapy, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$838 million (Q3 2026 ~$223 million, up ~13% year over year)
- Adjusted EBITDA (TTM): ~$100 million (2026 guidance $102 million to $106 million)
As of November 2026: Figures are approximate and tied to the asOf date; verify live numbers before acting. GAAP earnings are not a useful guide here, because the rising value of partners' stakes is charged against EPS without touching cash, which is why the company and analysts lean on adjusted EPS and EBITDA. Even on those measures the stock is not cheap after rising about 17% in three sessions after the report and holding most of that gain. Published analyst targets moved up after the quarter, with Barrington at $122, and the mean of about $111.50 across six analysts sits roughly 16% above the November 20 close.
Who competes with U.S. Physical Therapy, Inc. (USPH)?
Large outpatient therapy chains
Select Medical's Select Physical Therapy is the biggest listed peer, with roughly 1,900 outpatient locations inside a larger hospital and rehab company. Other chains such as ATI Physical Therapy, Athletico, Upstream Rehabilitation and Ivy Rehab compete for the same patients, therapists and practices to acquire, and several are backed by private equity buyers bidding for the same deals.
Hospital-owned outpatient therapy
Health systems run their own outpatient therapy departments and control physician referrals, which makes them both rivals and customers. USPH's NYU Langone alliance is a bet that partnering with these systems pays more than competing with them, but a hospital can also choose to build its own clinics or partner with another operator.
Digital MSK and occupational health
Hinge Health and Sword Health sell app-based musculoskeletal care to employers and health plans, aiming at the same back, knee and shoulder patients at lower cost. On the IIP side, Concentra and smaller occupational health firms compete for employer contracts covering workplace injury prevention and treatment.
What stocks are similar to U.S. Physical Therapy, Inc. (USPH)?
Other names that sit close to USPH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in U.S. Physical Therapy, Inc. (USPH)
There are three common ways to get USPH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so USPH sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where USPH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on U.S. Physical Therapy, Inc. (USPH)
USPH is a slow-growth clinic operator that just showed its hospital affiliations can lift earnings. At about $96 on November 20, 2026, after a 17% post-earnings jump to about $99.50 and a small pullback, the price already assumes 2027 delivers on that promise.
More on U.S. Physical Therapy, Inc. (USPH)
Whether USPH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is USPH a buy or a sell?, and where the stock could go from here in the USPH stock forecast.
For income investors, whether USPH pays a dividend and how the payout looks is covered in does USPH pay a dividend? And to weigh USPH against a peer, read the full side-by-side comparisons: USPH vs ATI and USPH vs HNGE.
Wondering how USPH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about U.S. Physical Therapy, Inc.
Ask Walnut's AI anything about USPH and see how it fits what you own.
FAQ
Is USPH stock worth owning right now?
+
That depends on how much you believe in the hospital affiliation story and what you are willing to pay for it. The business is steady: visits grew 8% in Q3 2026, revenue per visit hit a record $111, and adjusted EBITDA rose to about $28 million. Management reaffirmed 2026 adjusted EBITDA guidance of $102 million to $106 million. Against that, the stock rose from about $85 to about $99.50 in the three sessions after earnings, closed near $96.16 on November 20, 2026, and trades around 36x trailing adjusted EPS, below a mean analyst target of about $111.50 that rose after the report. Someone holding it already might weigh how large the position is relative to a portfolio, since this is a single small-cap healthcare name. Walnut is not an investment adviser, and this is not a recommendation.
What does U.S. Physical Therapy actually do?
+
It owns and manages outpatient physical and occupational therapy clinics, about 799 of them at September 30, 2026, treating patients recovering from surgery, sports injuries, back and joint pain, and workplace injuries. It also runs an industrial injury prevention business that places athletic trainers and ergonomic specialists at employer sites, which brought in about $33 million in Q3. Most clinics are run as partnerships: USPH buys a majority stake in a local practice and the founding therapists keep a minority stake and keep managing it. That approach keeps local leadership in place and gives therapists a share of the profits, which helps with retention in a field where therapists are hard to hire and harder to keep.
Why does USPH report a GAAP loss when adjusted earnings are growing?
+
It comes from the partnership structure. Partners in many clinics hold redeemable stakes that USPH may be required to buy later, and those stakes are carried on the balance sheet at about $357 million. When clinics perform better, the stakes become more valuable. Under GAAP that increase is excluded from net income but deducted in the earnings per share calculation. So in Q3 2026, USPH earned about $11 million in net income attributable to shareholders, yet reported a loss of $1.04 per share. Adjusted EPS, which removes that revaluation and other non-cash items like earnout changes, was $0.80. Analysts mostly use the adjusted figure, but the stakes are a real future claim on cash.
What are the hospital affiliations, and why do they matter?
+
In February 2026 USPH signed two 10-year alliances. Its Metro subsidiary moved 60 New York clinics into NYU Langone's clinical services network, and another partner moved 10 clinics into a local hospital system's network. By the end of Q3, 72 clinics were integrated and generated about $25 million of revenue in the quarter. These arrangements usually carry better rates and steadier referrals from the hospital's physicians. Management has said it expects that revenue to rise significantly, has a pipeline of other hospital prospects, and earlier pointed to at least $14 million of EBITDA lift in 2027. Much of the post-earnings rally reflects confidence that this lift arrives on schedule.
Does USPH pay a dividend?
+
Yes. The board declared a quarterly dividend of $0.46 per share on November 4, 2026, payable December 11 to shareholders of record on November 16. That works out to $1.84 a year, a yield of about 1.9% at a price near $96. The rate was raised from $0.45 in February 2026, and the company has paid a dividend for many years. The company has also bought back shares: in Q2 2026 it repurchased about 306,000 shares at an average of about $62.80, bringing total repurchases under its $25 million authorization to about $24.8 million. With borrowings at $247 million and acquisitions continuing, the dividend competes with deal spending for cash.
How did USPH do in its latest quarter?
+
Q3 2026, reported November 4, was its best quarter of the year. Revenue rose 13% to about $223 million, with physical therapy revenue of about $190 million (mature clinics up 6%) and IIP revenue of about $33 million (up 14%). Visits were 1.7 million, up 8%, and revenue per visit was a record $111. Adjusted EBITDA was about $28 million against $24 million a year earlier, and adjusted EPS was $0.80 against $0.66. Physical therapy margin held at 19%, with higher employee health benefit costs taking about 150 basis points off it. The company added 21 locations and closed three, finishing at 799, and reaffirmed full-year adjusted EBITDA guidance of $102 million to $106 million.
How has USPH stock performed in 2026?
+
It has been a round trip and then some. The shares ended 2025 near $78. They slid to about $59 in May after a Q1 report in which winter weather cost more than 31,000 visits and adjusted EBITDA of about $20.2 million came in below the roughly $21.8 million analysts expected. A Q2 adjusted EPS miss followed in August. The stock recovered over the summer as the hospital clinics came online, traded around $85 to $89 in late October, and then jumped to about $99.50 by November 6 after the Q3 report. It closed at about $96.16 on November 20, 2026, up about 22% for the year, about 24% over three months and about 41% from a year earlier, a few percent below its 52-week high of about $101.80. Past performance does not predict future returns, and Walnut is not an investment adviser.
What are the main risks of investing in USPH?
+
Reimbursement comes first: Medicare cut therapy rates for several years before 2026, and part of this year's increase came from a temporary boost, so the 2027 fee schedule matters. Commercial insurers can also squeeze rates. Labor is next, with therapist wages rising and the self-insured employee health plan running over budget. The partnership structure means about $357 million of partner stakes that may need to be bought back, and GAAP EPS has been negative in three of the last four quarters because of them. The hospital strategy leans heavily on one New York system. The CFO role changed hands in 2026. And after a 17% rise in three days in early November, the stock is priced for the 2027 improvement management has described, which leaves less cushion if results fall short.
What do analysts expect from USPH?
+
Six analysts cover the stock with a buy consensus and a mean price target of about $111.50 as of November 2026. Barrington raised its target to $110 from $98 on November 6 and to $122 on November 13, keeping an Outperform rating. Consensus calls for about $0.88 of adjusted EPS in Q4 2026, about $2.88 for 2026 and about $3.37 for 2027, on revenue of roughly $860 million and $932 million. Walnut is not an investment adviser.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with U.S. Physical Therapy, Inc.'s investor relations page or your broker before making investment decisions.